Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension

Carlo Arevalo; R James White; Daniel Lachant

doi:10.1016/j.rmcr.2022.101646

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension

Respir Med Case Rep. 2022 Apr 9:37:101646. doi: 10.1016/j.rmcr.2022.101646. eCollection 2022.

Authors

Carlo Arevalo¹, R James White², Daniel Lachant²

Affiliations

¹ Department of Medicine, Hospital Medicine Division, University of Rochester Medical Center, Rochester, NY, USA.
² Department of Medicine, Pulmonary and Critical Care Division, University of Rochester Medical Center, Rochester, NY, USA.

Abstract

There are no prospective studies or guidelines describing transition between selexipag and oral treprostinil. We present two different transition strategies from selexipag to oral treprostinil, one started inpatient and then completed at home, and one completely under outpatient settings. Neither patient experienced worsening prostacyclin-type adverse effects; both were rigorous in their attention to a 7-8 hour administration schedule for oral treprostinil, and both experienced objective clinical benefit at follow-up. Prospective studies are needed to help guide clinical decisions when patients remain intermediate risk after a trial of either drug.

Publication types

Case Reports